Treating the Side Effects of Exogenous Glucocorticoids; Can We Separate the Good From the Bad?
Open accessThe DOI matches its Crossref record; 124 of the 124 references it cites were found in a registry or an index.
Abstract
It is estimated that 2% to 3% of the population are currently prescribed systemic or topical glucocorticoid treatment. The potent anti-inflammatory action of glucocorticoids to deliver therapeutic benefit is not in doubt. However, the side effects associated with their use, including central weight gain, hypertension, insulin resistance, type 2 diabetes (T2D), and osteoporosis, often collectively termed iatrogenic Cushing's syndrome, are associated with a significant health and economic burden. The precise cellular mechanisms underpinning the differential action of glucocorticoids to drive the desirable and undesirable effects are still not completely understood. Faced with the unmet clinical need to limit glucocorticoid-induced adverse effects alongside ensuring the preservation of anti-inflammatory actions, several strategies have been pursued. The coprescription of existing licensed drugs to treat incident adverse effects can be effective, but data examining the prevention of adverse effects are limited. Novel selective glucocorticoid receptor agonists and selective glucocorticoid receptor modulators have been designed that aim to specifically and selectively activate anti-inflammatory responses based upon their interaction with the glucocorticoid receptor. Several of these compounds are currently in clinical trials to evaluate their efficacy. More recently, strategies exploiting tissue-specific glucocorticoid metabolism through the isoforms of 11β-hydroxysteroid dehydrogenase has shown early potential, although data from clinical trials are limited. The aim of any treatment is to maximize benefit while minimizing risk, and within this review we define the adverse effect profile associated with glucocorticoid use and evaluate current and developing strategies that aim to limit side effects but preserve desirable therapeutic efficacy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2020 International Society of Hypertension Global Hypertension Practice Guidelines
Unger, T., Borghi, C., Charchar, F., Khan, N. A., Poulter, N. R., Prabhakaran, D., Ramirez, A., Schlaich, M., Stergiou, G. S., Tomaszewski, M., et al. (2020) · Hypertension · doi:10.1161/hypertensionaha.120.15026 · Cited by 4,132 · cited 1×
“However, in selected cases, such as those patients with previous myocardial infarction, vasodilating beta-blockers (including carvedilol, labeta-lol, and nebivolol) may be considered, as benefits to improve cardiovascular risk related to myocardial infarction might outweigh other risks (437, 439).”
BackgroundThe Metabolic Syndrome and Cardiovascular Risk
Mottillo, S., Filion, K. B., Genest, J., Joseph, L., Pilote, L., Poirier, P., Rinfret, S., Schiffrin, E. L., & Eisenberg, M. J. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.05.034 · Cited by 3,009
Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes
Bakris, G. L., Agarwal, R., Anker, S. D., Pitt, B., Ruilope, L. M., Rossing, P., Kolkhof, P., Nowack, C., Schloemer, P., Joseph, A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2025845 · Cited by 2,935 · cited 1×
“However, it has demonstrated only modest effects on blood pressure reduction (434), lower efficacy, and risk of adverse events including hy-perkalaemia when compared to spironolactone (435), and, therefore, it might not be an alternative option.”
BackgroundDahlöf, B., Sever, P. S., Poulter, N. R., Wedel, H., Beevers, D. G., Caulfield, M., Collins, R., Kjeldsen, S. E., Kristinsson, A., McInnes, G. T., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67185-1 · Cited by 2,909
Williams, B., Mancia, G., Spiering, W., Agabiti Rosei, E., Azizi, M., Burnier, M., Clement, D. L., Coca, A., de Simone, G., Dominiczak, A., et al. (2018) · Journal of Hypertension · doi:10.1097/hjh.0000000000001940 · Cited by 2,885
Diagnosis and classification of diabetes mellitus
American Diabetes Association (2013) · Diabetes Care · doi:10.2337/dc13-s067 · Cited by 2,245
Metabolic Syndrome and Risk of Incident Cardiovascular Events and Death
Gami, A. S., Witt, B. J., Howard, D. E., Erwin, P. J., Gami, L. A., Somers, V. K., & Montori, V. M. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.09.032 · Cited by 1,888
Immune regulation by glucocorticoids
Cain, D. W., & Cidlowski, J. A. (2017) · Nature Reviews Immunology · doi:10.1038/nri.2017.1 · Cited by 1,846
Yki-Järvinen, H. (2004) · New England Journal of Medicine · doi:10.1056/nejmra041001 · Cited by 1,830
Chromatin accessibility and the regulatory epigenome
Klemm, S. L., Shipony, Z., & Greenleaf, W. J. (2019) · Nature Reviews Genetics · doi:10.1038/s41576-018-0089-8 · Cited by 1,793 · cited 1×
“Here GR plays an important role in recruitment of chromatin remodeling enzymes that open the DNA and thus allow access for transcription to occur ( 120).”
BackgroundBornstein, S. R., Allolio, B., Arlt, W., Barthel, A., Don-Wauchope, A., Hammer, G. D., Husebye, E. S., Merke, D. P., Murad, M. H., Stratakis, C. A., et al. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-1710 · Cited by 1,769 · cited 1×
“In endocrine disease, prescribed GCs are used for the diagnosis of Cushing’s syndrome (mainly dexametha - sone), but, more importantly, they are crucial for the management of adrenal insufficiency (11) and congenital adrenal hyperplasia (CAH) (12 ).”
BackgroundWeinstein, R. S., Jilka, R. L., Parfitt, A. M., & Manolagas, S. C. (1998) · Journal of Clinical Investigation · doi:10.1172/jci2799 · Cited by 1,753 · cited 1×
“Briefly, GCs increase osteocyte apoptosis and suppress osteoblasts activity and therefore limit bone formation (249) while increasing osteoclast-mediated bone resorption (250, 251).”
BackgroundYang-Yen, H.-F., Chambard, J.-C., Sun, Y.-L., Smeal, T., Schmidt, T. J., Drouin, J., & Karin, M. (1990) · Cell · doi:10.1016/0092-8674(90)90396-v · Cited by 1,553 · cited 1×
“There are several key transcription factors that have been implicated, including AP-1, NFkB, and STAT3 (105, 128, 129).”
BackgroundCrystallographic analysis of the interaction of the glucocorticoid receptor with DNA
Luisi, B. F., Xu, W. X., Otwinowski, Z., Freedman, L. P., Yamamoto, K. R., & Sigler, P. B. (1991) · Nature · doi:10.1038/352497a0 · Cited by 1,503 · cited 1×
“Once in the nucleus, GR binds to the DNA, detecting a cognate sequence in the major groove (91).”
BackgroundSpeiser, P. W., Azziz, R., Baskin, L. S., Ghizzoni, L., Hensle, T. W., Merke, D. P., Meyer-Bahlburg, H. F. L., Miller, W. L., Montori, V. M., Oberfield, S. E., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2631 · Cited by 1,468 · cited 6×
“Conversely, supraphysiological (and still occasionally reverse-circadian) doses are often needed to control patients with CAH.”
BackgroundInfluentialThe epidemiology of corticosteroid-induced osteoporosis: a meta-analysis
Staa, T. P. V., Staa, T. P. V., Staa, T. P. V., Leufkens, H. G. M., & Cooper, C. (2002) · Osteoporosis International · doi:10.1007/s001980200108 · Cited by 1,294 · cited 2×
“However, risk decreases significantly when treatment is ceased, although whether it returns to baseline values is unclear (267).”
BackgroundUse of oral corticosteroids and risk of fractures
Van Staa, T. P., Leufkens, H. G. M., Abenhaim, L., Zhang, B., & Cooper, C. (2000) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2000.15.6.993 · Cited by 1,263
Alendronate for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis
Saag, K. G., Emkey, R., Schnitzer, T. J., Brown, J. P., Hawkins, F., Goemaere, S., Thamsborg, G., Liberman, U. A., Delmas, P. D., Malice, M.-P., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199807303390502 · Cited by 1,258
Tang, B. M., Eslick, G. D., Nowson, C., Smith, C., & Bensoussan, A. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61342-7 · Cited by 1,248
DNA binding of the glucocorticoid receptor is not essential for survival
Reichardt, H. M., Kaestner, K. H., Tuckermann, J., Kretz, O., Wessely, O., Bock, R., Gass, P., Schmid, W., Herrlich, P., Angel, P., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81183-6 · Cited by 1,068 · cited 1×
“The tethering concept led to the development of the GRA46T mutant mouse, termed GRdim, which lacks dimerization capacity (107) and has been used extensively to study the dissociation of inflammatory repression by GCs from the metabolic actions of GCs, which were suggested to be dependent on dimer…”
Method11β-Hydroxysteroid dehydrogenase type 1: a tissue specific regulator of glucocorticoid response
Tomlinson, J. W., Walker, E. A., Bujalska, I. J., Draper, N., Lavery, G. G., Cooper, M. S., Hewison, M., & Stewart, P. M. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0031 · Cited by 969 · cited 4×
“11 β -HSD1 is highly expressed in many tissues through - out the body including the liver, which has the highest level of expression, adipose (subcutaneous and intrabdominal), muscle, skin, brain, and bone (25).”
InfluentialSelf-citationSystemic Adverse Effects of Inhaled Corticosteroid Therapy: A Systematic Review and Meta-analysis
Lipworth, B. J. (1999) · Archives of Internal Medicine · doi:10.1001/archinte.159.9.941 · Cited by 918
Teriparatide or Alendronate in Glucocorticoid-Induced Osteoporosis
Saag, K. G., Shane, E., Boonen, S., Marín, F., Donley, D. W., Taylor, K. A., Dalsky, G. P., & Marcus, R. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa071408 · Cited by 914
Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin
Plotkin, L. I., Weinstein, R. S., Parfitt, A. M., Roberson, P. K., Manolagas, S. C., & Bellido, T. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6800 · Cited by 890 · cited 16×
“The only osteoanabolic agent that has been studied in RCTs in GIOP is teriparatide, the recombinant 34 amino acid peptide of PTH.”
BackgroundInfluentialPharmacokinetics and pharmacodynamics of systemically administered glucocorticoids.
Czock, D., Keller, F., Rasche, F. M., & H??ussler, U. (2005) · Clinical Pharmacokinetics · doi:10.2165/00003088-200544010-00003 · Cited by 886
6. Glycemic Targets: Standards of Medical Care in Diabetes—2021
American Diabetes Association (2021) · Diabetes Care · doi:10.2337/dc21-s006 · Cited by 847 · cited 2×
“The American Diabetes Association suggests using similar targets as for other types of diabetes, aiming to individualize glycemic control according to patient-specific factors including life expectancy, comorbidities, compliance, and risk of hypo-glycemia (402).”
BackgroundWaljee, A. K., Rogers, M. A. M., Lin, P., Singal, A. G., Stein, J. D., Marks, R. M., Ayanian, J. Z., & Nallamothu, B. K. (2017) · BMJ · doi:10.1136/bmj.j1415 · Cited by 830
Arlt, W., & Allolio, B. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13492-7 · Cited by 819
Bledsoe, R. K., Montana, V. G., Stanley, T. B., Delves, C. J., Apolito, C. J., McKee, D. D., Consler, T. G., Parks, D. J., Stewart, E. L., Willson, T. M., et al. (2002) · Cell · doi:10.1016/s0092-8674(02)00817-6 · Cited by 818
Hofbauer, L. C., Gori, F., Riggs, B. L., Lacey, D. L., Dunstan, C. R., Spelsberg, T. C., & Khosla, S. (1999) · Endocrinology · doi:10.1210/endo.140.10.7034 · Cited by 794 · cited 2×
“Briefly, GCs increase osteocyte apoptosis and suppress osteoblasts activity and therefore limit bone formation (249) while increasing osteoclast-mediated bone resorption (250, 251).”
BackgroundDoes central obesity reflect “Cushing's disease of the omentum”?
Bujalska, I. J., Kumar, S., & Stewart, P. M. (1997) · The Lancet · doi:10.1016/s0140-6736(96)11222-8 · Cited by 753 · cited 1×
“Importantly, GCs also increase the expression and activity of 11 β -HSD1, and therefore there is an additional “feed-forward” mechanism that further fuels GC availability and action within tissues ( 493).”
BackgroundDNA binding site sequence directs glucocorticoid receptor structure and activity
Meijsing, S. H., Pufall, M. A., So, A. Y., Bates, D. L., Chen, L., & Yamamoto, K. R. (2009) · Science · doi:10.1126/science.1164265 · Cited by 673 · cited 1×
“This DNA-based modulation of GR thus adds a fine-tuning mechanism to the GC response at specific genes (94, 95).”
BackgroundDose-related patterns of glucocorticoid-induced side effects
Huscher, D., Thiele, K., Gromnica-Ihle, E., Hein, G., Demary, W., Dreher, R., Zink, A., & Buttgereit, F. (2009) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.092163 · Cited by 604 · cited 2×
“However, the duration of exposure and daily dosage are thought to be important (41-43), as well as a family history of essential hypertension (224).”
BackgroundPopulation‐based assessment of adverse events associated with long‐term glucocorticoid use
Curtis, J. R., Westfall, A. O., Allison, J., Bijlsma, J. W., Freeman, A., George, V., Kovac, S. H., Spettell, C. M., & Saag, K. G. (2006) · Arthritis Care & Research · doi:10.1002/art.21984 · Cited by 595
Surjit, M., Ganti, K. P., Mukherji, A., Ye, T., Hua, G., Metzger, D., Li, M., & Chambon, P. (2011) · Cell · doi:10.1016/j.cell.2011.03.027 · Cited by 551 · cited 1×
“While it has been postulated that nGREs are found throughout the genome and represent a key determinant of GR-mediated gene repression (132), these findings have not been corroborated by cistromic studies (133, 134).”
BackgroundThe Functional and Clinical Significance of the 24-Hour Rhythm of Circulating Glucocorticoids
Oster, H., Challet, E., Ott, V., Arvat, E., de Kloet, E. R., Dijk, D.-J., Lightman, S., Vgontzas, A., & Van Cauter, E. (2017) · Endocrine Reviews · doi:10.1210/er.2015-1080 · Cited by 548
Decreased memory performance in healthy humans induced by stress-level cortisol treatment
Newcomer, J. W. (1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.6.527 · Cited by 546 · cited 2×
“Both short-term (351, 352) and long-term (353) GC treatment can adversely affect memory performance (354, 355) with a more significant decline in elderly patients (354, 356).”
BackgroundGlucocorticoid receptor control of transcription: precision and plasticity via allostery
Weikum, E. R., Knuesel, M. T., Ortlund, E. A., & Yamamoto, K. R. (2017) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2016.152 · Cited by 533 · cited 1×
“Full exploration of the structure of GR is beyond the scope of this review and has been reviewed extensively elsewhere (73, 74).”
Use of oral corticosteroids in the United Kingdom
van Staa, T. P. (2000) · QJM · doi:10.1093/qjmed/93.2.105 · Cited by 529
Glucocorticoid-induced hyperglycemia
Clore, J. N., & Thurby-Hay, L. (2009) · Endocrine Practice · doi:10.4158/ep08331.rar · Cited by 508
Saag, K. G., Zanchetta, J. R., Devogelaer, J., Adler, R. A., Eastell, R., See, K., Krege, J. H., Krohn, K., & Warner, M. R. (2009) · Arthritis & Rheumatism · doi:10.1002/art.24879 · Cited by 493
Adrenal insufficiency in corticosteroids use: systematic review and meta-analysis
Broersen, L. H. A., Pereira, A. M., Jørgensen, J. O. L., & Dekkers, O. M. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-1218 · Cited by 456
Glucocorticoid-Induced Osteoporosis
Buckley, L., & Humphrey, M. B. (2018) · New England Journal of Medicine · doi:10.1056/nejmcp1800214 · Cited by 438
Prevalence of oral glucocorticoid usage in the United States: a general population perspective
Overman, R. A., Yeh, J., & Deal, C. L. (2013) · Arthritis Care & Research · doi:10.1002/acr.21796 · Cited by 405
Walsh, L. J., Wong, C. A., Pringle, M., & Tattersfield, A. E. (1996) · BMJ · doi:10.1136/bmj.313.7053.344 · Cited by 383
Strähle, U., Klock, G., & Schütz, G. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.22.7871 · Cited by 355
Saad, M. J., Folli, F., Kahn, J. A., & Kahn, C. R. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116803 · Cited by 349
Johannsson, G., Nilsson, A. G., Bergthorsdottir, R., Burman, P., Dahlqvist, P., Ekman, B., Engström, B. E., Olsson, T., Ragnarsson, O., Ryberg, M., et al. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-1926 · Cited by 329
Deciphering the Phosphorylation “Code” of the Glucocorticoid Receptor in Vivo
Wang, Z., Frederick, J., & Garabedian, M. J. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m110530200 · Cited by 321 · cited 1×
“Ser203 appears to be a preactivation step that must occur before the Ser211 phosphorylation, which confers full activation (85), and, as a result, Ser203 phosphorylated GR can be found in the cytoplasm, while Ser211 is almost exclusively nuclear (86).”
BackgroundPrevalence of long-term oral glucocorticoid prescriptions in the UK over the past 20 years
Fardet, L., Petersen, I., & Nazareth, I. (2011) · Rheumatology · doi:10.1093/rheumatology/ker017 · Cited by 319
Modulation of Glucocorticoid Receptor Function via Phosphorylation
ISMAILI, N., & GARABEDIAN, M. J. (2004) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1321.007 · Cited by 318
Glucocorticoids and the risk for initiation of hypoglycemic therapy
Gurwitz, J. H. (1994) · Archives of Internal Medicine · doi:10.1001/archinte.1994.00420010131015 · Cited by 314
Cortisol variation in humans affects memory for emotionally laden and neutral information.
Abercrombie, H. C., Kalin, N. H., Thurow, M. E., Rosenkranz, M. A., & Davidson, R. J. (2003) · Behavioral Neuroscience · doi:10.1037/0735-7044.117.3.505 · Cited by 309 · cited 1×
“Both short-term (351, 352) and long-term (353) GC treatment can adversely affect memory performance (354, 355) with a more significant decline in elderly patients (354, 356).”
BackgroundGlucocorticoids—All-Rounders Tackling the Versatile Players of the Immune System
Strehl, C., Ehlers, L., Gaber, T., & Buttgereit, F. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01744 · Cited by 308
Non-genomic effects of glucocorticoids: an updated view
Panettieri, R. A., Schaafsma, D., Amrani, Y., Koziol-White, C., Ostrom, R., & Tliba, O. (2019) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2018.11.002 · Cited by 297 · cited 1×
“Much attention has been focussed on the very potent effects of GCs that rely on transcription and then translation to have their effects (141).”
BackgroundAntagonism of glucocorticoid receptor transcriptional activation by the c-Jun N-terminal kinase
Rogatsky, I., Logan, S. K., & Garabedian, M. J. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.5.2050 · Cited by 297 · cited 1×
“Once ligand is bound, GR is phosphorylated at multiple sites (Ser203 and Ser211) by various kinases, including CDKs and MAPKs (82-84).”
BackgroundVandevyver, S., Dejager, L., Tuckermann, J., & Libert, C. (2013) · Endocrinology · doi:10.1210/en.2012-2045 · Cited by 296 · cited 1×
“…Hormone Action section, this model of GC action is no longer clear-cut; monomers have been found to activate and not simply repress gene expression (114), and also to activate anti-inflammatory genes that are required for the full effects of GCs to act as anti-inflammatory agents (111, 479, 480).”
BackgroundListing, J., Kekow, J., Manger, B., Burmester, G.-R., Pattloch, D., Zink, A., & Strangfeld, A. (2015) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-204021 · Cited by 295
Direct Effect of Glucocorticoids on Lipolysis in Adipocytes
Xu, C., He, J., Jiang, H., Zu, L., Zhai, W., Pu, S., & Xu, G. (2009) · Molecular Endocrinology · doi:10.1210/me.2008-0464 · Cited by 291 · cited 1×
“GCs also act on other tissues shuttling gluconeogenic pre-cursors to the liver, for example, by increasing lipolysis in white adipose tissue (187) and protein catabolism in skeletal muscle (188) and therefore driving glucose production and fueling the development of hepatic steatosis (189).”
BackgroundFardet, L., Petersen, I., & Nazareth, I. (2012) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.11071009 · Cited by 287
Drouin, J., Trifiro, M. A., Plante, R. K., Nemer, M., Eriksson, P., & Wrange, Ö. (1989) · Molecular and Cellular Biology · doi:10.1128/mcb.9.12.5305-5314.1989 · Cited by 283 · cited 1×
“For example, these putative nGREs have been found in the POMC and CRH genes and have been suggested to be a major part of how GCs cause negative feedback on the hypothalamo–pituitary–adrenal (HPA) axis (130, 131).”
BackgroundGlucocorticoid Receptor Phosphorylation Differentially Affects Target Gene Expression
Chen, W., Dang, T., Blind, R. D., Wang, Z., Cavasotto, C. N., Hittelman, A. B., Rogatsky, I., Logan, S. K., & Garabedian, M. J. (2008) · Molecular Endocrinology · doi:10.1210/me.2007-0219 · Cited by 280 · cited 1×
“Different phosphorylation levels of GR have also been linked to differential transcriptional activity (88, 89) and its ability to recruit chromatin remodeling complexes (90).”
BackgroundHigh cardiovascular risk in patients with Cushing’s syndrome according to 1999 WHO/ISH guidelines
Mancini, T., Kola, B., Mantero, F., Boscaro, M., & Arnaldi, G. (2004) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2004.02168.x · Cited by 278 · cited 1×
“More than half of patients with endogenous GC excess have apparently normal fasting glycemia (198) and oral glucose tolerance testing (OGTT) is not routinely performed (199).”
BackgroundUhlenhaut, N. H., Barish, G. D., Yu, R. T., Downes, M., Karunasiri, M., Liddle, C., Schwalie, P., Hübner, N., & Evans, R. M. (2013) · Molecular Cell · doi:10.1016/j.molcel.2012.10.013 · Cited by 265 · cited 3×
“The recruitment of repression-specific cofactors also plays a core role in determining which genes are repressed by GR (134).”
BackgroundHuizenga, N. A. T. M. (1998) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.83.1.144 · Cited by 265
del Rincón, I., Battafarano, D. F., Restrepo, J. F., Erikson, J. M., & Escalante, A. (2014) · Arthritis & Rheumatology · doi:10.1002/art.38210 · Cited by 264 · cited 5×
“The majority of the published studies have largely focussed on all-cause mor - tality, although some have also specifically looked at cardio-vascular mortality (60, 63, 165-168).”
BackgroundResultInfluentialGlucocorticoids and bone: consequences of endogenous and exogenous excess and replacement therapy
Hardy, R. S., Zhou, H., Seibel, M. J., & Cooper, M. S. (2018) · Endocrine Reviews · doi:10.1210/er.2018-00097 · Cited by 258 · cited 5×
“Although fractures are most commonly seen at these sites, they can occur at virtually any skeletal site (59, 256).”
BackgroundInfluentialPrevalence and predictors of corticosteroid-related hyperglycemia in hospitalized patients
Donihi, A. C., Raval, D., Saul, M., Korytkowski, M. T., & DeVita, M. A. (2006) · Endocrine Practice · doi:10.4158/ep.12.4.358 · Cited by 246 · cited 3×
“A recent meta-analysis identified that the risk of GC-induced DM was greatest in subjects with abdominal adiposity and in those taking higher doses of GCs and for longer periods (70, 205).”
BackgroundRuzzin, J., Wagman, A. S., & Jensen, J. (2005) · Diabetologia · doi:10.1007/s00125-005-1886-0 · Cited by 243 · cited 1×
“GCs directly disrupt insulin signaling in skeletal muscle by downregulating the expression and phosphorylation of IRS1, PI3K, and PKB–AKT (193-195).”
BackgroundAdverse events of low- to medium-dose oral glucocorticoids in inflammatory diseases: a meta-analysis
Hoes, J. N., Jacobs, J. W. G., Verstappen, S. M. M., Bijlsma, J. W. J., & Van der Heijden, G. J. M. G. (2009) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.100008 · Cited by 243 · cited 1×
“Fracture is the most common, serious, and preventable adverse event associated with GC use (263, 264).”
BackgroundItoh, M., Adachi, M., Yasui, H., Takekawa, M., Tanaka, H., & Imai, K. (2002) · Molecular Endocrinology · doi:10.1210/me.2002-0144 · Cited by 238
Grøntved, L., John, S., Baek, S., Liu, Y., Buckley, J. R., Vinson, C., Aguilera, G., & Hager, G. L. (2013) · The EMBO Journal · doi:10.1038/emboj.2013.106 · Cited by 229 · cited 1×
“While it has been postulated that nGREs are found throughout the genome and represent a key determinant of GR-mediated gene repression (132), these findings have not been corroborated by cistromic studies (133, 134).”
BackgroundExogenous cushing’s syndrome and glucocorticoid withdrawal
Hopkins, R. L., & Leinung, M. C. (2005) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2005.01.013 · Cited by 224 · cited 1×
“…inhaled, intranasal, and intra-articular) might limit the incidence of system ad - verse effects, there is now good evidence documenting the systemic bioavailability (see also Table 2) and adverse effects (notably adrenal suppression) associated with administration of GCs via all routes (26-32).”
BackgroundDiscrimination between NL1- and NL2-Mediated Nuclear Localization of the Glucocorticoid Receptor
Savory, J. G. A., Hsu, B., Laquian, I. R., Giffin, W., Reich, T., Haché, R. J. G., & Lefebvre, Y. A. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.2.1025 · Cited by 222 · cited 2×
“Indeed, transport into the nucleus also can occur at a rate similar to that of diffusion, as has been demonstrated using nuclear localization sequence 1 mutants (80).”
BackgroundDiurnal variation in suppression of adrenal function by glucocorticoids
NICHOLS, T., NUGENT, C. A., & TYLER, F. H. (1965) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-25-3-343 · Cited by 217
Grossmann, C., Scholz, T., Rochel, M., Bumke-Vogt, C., Oelkers, W., Pfeiffer, A., Diederich, S., & Bahr, V (2004) · European Journal of Endocrinology · doi:10.1530/eje.0.1510397 · Cited by 212 · cited 1×
“In contrast, a hydrophilic substituent at position 16 decreases both MC and GC properties (20).”
BackgroundIsidori, A. M., Venneri, M. A., Graziadio, C., Simeoli, C., Fiore, D., Hasenmajer, V., Sbardella, E., Gianfrilli, D., Pozza, C., Pasqualetti, P., et al. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30398-4 · Cited by 211
Risk of Diabetes Associated With Prescribed Glucocorticoids in a Large Population
Gulliford, M. C., Charlton, J., & Latinovic, R. (2006) · Diabetes Care · doi:10.2337/dc06-1499 · Cited by 211
Incidence of Venous Thromboembolism in Patients with Cushing's Syndrome: A Multicenter Cohort Study
Stuijver, D. J. F., van Zaane, B., Feelders, R. A., Debeij, J., Cannegieter, S. C., Hermus, A. R., van den Berg, G., Pereira, A. M., de Herder, W. W., Wagenmakers, M. A. E. M., et al. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-1661 · Cited by 208
Continuous monitoring of circadian glycemic patterns in patients receiving prednisolone for COPD
Burt, M. G., Roberts, G. W., Aguilar-Loza, N. R., Frith, P., & Stranks, S. N. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-2729 · Cited by 203 · cited 1×
“…therapy should be started when pre-or post-prandial glucose repeatedly exceed 140 mg/dL (7.8 mmol/L) or 200 mg/dL (11.1 mmol/L), respectively (399-401), and similar treatment strategies used in patients with T2D, including a stepwise intensification of anti-hyperglycemic therapy as well as…”
MethodInfluentialCooper, M. S., Rabbitt, E. H., Goddard, P. E., Bartlett, W. A., Hewison, M., & Stewart, P. M. (2002) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2002.17.6.979 · Cited by 200
George, M. D., Baker, J. F., Winthrop, K., Hsu, J. Y., Wu, Q., Chen, L., Xie, F., Yun, H., & Curtis, J. R. (2020) · Annals of Internal Medicine · doi:10.7326/m20-1594 · Cited by 198 · cited 1×
“However, several retrospective studies have suggested that lower doses ( ≤ 5 mg PE/day) are also associated with a clinically meaningful increase in serious infection risk (388, 390, 394), especially when given for a prolonged duration ( > 3 months) (391).”
Background11β-hydroxysteroid dehydrogenase 1: translational and therapeutic aspects
Gathercole, L. L., Lavery, G. G., Morgan, S. A., Cooper, M. S., Sinclair, A. J., Tomlinson, J. W., & Stewart, P. M. (2013) · Endocrine Reviews · doi:10.1210/er.2012-1050 · Cited by 196
Self-citationReversible steroid dementia in patients without steroid psychosis
(1984) · American Journal of Psychiatry · doi:10.1176/ajp.141.3.369 · Cited by 194 · cited 2×
“Several reports have documented complete cognitive recovery within weeks of GC discontinuation (365, 366), but long-term (up to 1 year) persistence of mild cognitive impairment has also been described (351, 367) (Table 3).”
BackgroundDiabetes in Cushing syndrome: basic and clinical aspects
Mazziotti, G., Gazzaruso, C., & Giustina, A. (2011) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2011.09.001 · Cited by 193 · cited 1×
“Lifestyle modifications (hypocaloric diet and adequate low-moderate physical activity) are currently recommended for high-risk subjects predisposed to DM, but it should be recommended for all patients undergoing treatment with GCs (404).”
BackgroundPathophysiology of Diabetes Mellitus in Cushing’s Syndrome
Pivonello, R., De Leo, M., Vitale, P., Cozzolino, A., Simeoli, C., De Martino, M. C., Lombardi, G., & Colao, A. (2010) · Neuroendocrinology · doi:10.1159/000314319 · Cited by 190
Mallappa, A., Sinaii, N., Kumar, P., Whitaker, M. J., Daley, L.-A., Digweed, D., Eckland, D. J. A., Van Ryzin, C., Nieman, L. K., Arlt, W., et al. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-3809 · Cited by 167
Andela, C. D., van Haalen, F. M., Ragnarsson, O., Papakokkinou, E., Johannsson, G., Santos, A., Webb, S. M., Biermasz, N. R., van der Wee, N. J. A., & Pereira, A. M. (2015) · European Journal of Endocrinology · doi:10.1530/eje-14-1101 · Cited by 164 · cited 1×
“Chronic exposure to supraphysiological doses of GC dose is associated with anatomical brain changes and an increased prevalence of psychiatric disease, cognitive impairment, mood alterations, and sleep disturbance (344-346).”
BackgroundRoberts, A., James, J., Dhatariya, K., & Care, T. J. B. D. S. (. F. I. (2018) · Diabetic Medicine · doi:10.1111/dme.13675 · Cited by 158
Diederich, S., Eigendorff, E., Burkhardt, P., Quinkler, M., Bumke-Vogt, C., Rochel, M., Seidelmann, D., Esperling, P., Oelkers, W., & Bähr, V. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-020970 · Cited by 154
Fractures and bone mineral density in adult women with 21-hydroxylase deficiency
Falhammar, H., Filipsson, H., Holmdahl, G., Janson, P.-O., Nordenskjöld, A., Hagenfeldt, K., & Thorén, M. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-0744 · Cited by 151 · cited 1×
“Overall, BMD appears to be reduced at all skeletal sites in CAH, and, as for patients with Addison’s disease, this reduction correlates with cumulative GC exposure in some (289) but not all the studies (290).”
BackgroundGlucose Metabolism Abnormalities in Cushing Syndrome: From Molecular Basis to Clinical Management
Scaroni, C., Zilio, M., Foti, M., & Boscaro, M. (2017) · Endocrine Reviews · doi:10.1210/er.2016-1105 · Cited by 140 · cited 1×
“In this study, fasting plasma glucose concentrations were consistently below 100 mg/dL (5.55 nmol/L) and therefore cannot be relied upon to confirm the diagnosis (212).”
BackgroundInfluentialExcess mortality associated with hypopituitarism in adults: a meta-analysis of observational studies
Pappachan, J. M., Raskauskiene, D., Kutty, V. R., & Clayton, R. N. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-3787 · Cited by 138
Glucocorticoid-induced diabetes mellitus: prevalence and risk factors in primary renal diseases
Uzu, T., Harada, T., Sakaguchi, M., Kanasaki, M., Isshiki, K., Araki, S., Sugiomoto, T., Koya, D., Haneda, M., Kashiwagi, A., et al. (2006) · Nephron Clinical Practice · doi:10.1159/000097598 · Cited by 136 · cited 6×
“There are several distinct, concurrent pathophysiological mechanisms that are responsible for GC-induced insulin resistance and the onset of DM in patients with GC excess (68, 72, 183, 184).”
BackgroundInfluentialSchäcke, H., Zollner, T., Döcke, W., Rehwinkel, H., Jaroch, S., Skuballa, W., Neuhaus, R., May, E., Zügel, U., & Asadullah, K. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00238.x · Cited by 121
Whitaker, M. J., Debono, M., Huatan, H., Merke, D. P., Arlt, W., & Ross, R. J. (2014) · Clinical Endocrinology · doi:10.1111/cen.12316 · Cited by 121
Hypertension in Cushing’s Syndrome: From Pathogenesis to Treatment
Cicala, M. V., & Mantero, F. (2010) · Neuroendocrinology · doi:10.1159/000314315 · Cited by 112 · cited 1×
“Beta-blockers and thiazide diuretics should be used with caution; both may have unfavorable effects on glucose metabolism, and thiazide may worsen pre-existing hypokalemia (430, 436-438).”
BackgroundBénard-Laribière, A., Pariente, A., Pambrun, E., Bégaud, B., Fardet, L., & Noize, P. (2017) · BMJ Open · doi:10.1136/bmjopen-2017-015905 · Cited by 111
A practical guide for the management of steroid induced hyperglycaemia in the hospital
Aberer, F., Hochfellner, D. A., Sourij, H., & Mader, J. K. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10102154 · Cited by 110
van Raalte, D. H., Brands, M., van der Zijl, N. J., Muskiet, M. H., Pouwels, P. J. W., Ackermans, M. T., Sauerwein, H. P., Serlie, M. J., & Diamant, M. (2011) · Diabetologia · doi:10.1007/s00125-011-2174-9 · Cited by 109 · cited 1×
“In a very small study, there is evidence to suggest that even low, supraphysiological doses of GCs (prednisolone 7.5 mg daily) can impair glucose tolerance with prolonged administration (57), although this has not been confirmed in larger cohorts.”
BackgroundInfluentialModified-Release Hydrocortisone in Congenital Adrenal Hyperplasia
Merke, D. P., Mallappa, A., Arlt, W., Brac de la Perriere, A., Lindén Hirschberg, A., Juul, A., Newell-Price, J., Perry, C. G., Prete, A., Rees, D. A., et al. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab051 · Cited by 109 · cited 1×
“…(morning biochemical control of 17OHP and androstenedione), reduction in total daily dose and patients’ reported outcomes, the phase 3 study (559) failed to meet its primary endpoint (change from baseline to 24 weeks in the mean of the 24-hour 17OHP), probably for the prespecified methods…”
BackgroundWajngot, A., Giacca, A., Grill, V, Vranic, M., & Efendic, S. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.13.6035 · Cited by 105
Cardiovascular risk in Cushing’s syndrome
Arnaldi, G., Mancini, T., Polenta, B., & Boscaro, M. (2004) · Pituitary · doi:10.1007/s11102-005-1172-7 · Cited by 103 · cited 1×
“More than half of patients with endogenous GC excess have apparently normal fasting glycemia (198) and oral glucose tolerance testing (OGTT) is not routinely performed (199).”
BackgroundSTOCH, S. A., SAAG, K. G., GREENWALD, M., SEBBA, A. I., COHEN, S., VERBRUGGEN, N., GIEZEK, H., WEST, J., & SCHNITZER, T. J. (2009) · The Journal of Rheumatology · doi:10.3899/jrheum.081207 · Cited by 100
Glucocorticoid receptor polymorphisms and haplotypes and their expression in health and disease
Koper, J. W., van Rossum, E. F. C., & van den Akker, E. L. T. (2014) · Steroids · doi:10.1016/j.steroids.2014.07.015 · Cited by 97
Crowley, R. K., Argese, N., Tomlinson, J. W., & Stewart, P. M. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-2476 · Cited by 97
Lavery, G. G., Walker, E. A., Tiganescu, A., Ride, J. P., Shackleton, C. H. L., Tomlinson, J. W., Connell, J. M. C., Ray, D. W., Biason-Lauber, A., Malunowicz, E. M., et al. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0743 · Cited by 95
Self-citationFifteen-year nationwide trends in systemic glucocorticoid drug use in Denmark
Laugesen, K., Jørgensen, J. O. L., Petersen, I., & Sørensen, H. T. (2019) · European Journal of Endocrinology · doi:10.1530/eje-19-0305 · Cited by 92
Matthews, L., Berry, A., Ohanian, V., Ohanian, J., Garside, H., & Ray, D. (2008) · Molecular Endocrinology · doi:10.1210/me.2007-0154 · Cited by 88 · cited 1×
“GR activation promotes protein kinase A activa - tion to regulate chloride release (142), AMPK and CAMKII inhibition to limit glucose uptake (143), p38 and JNK activation (144) and Akt, GSK3B, and mTOR activation to regulate proliferation (145).”
BackgroundSelf-citationApparent mineralocorticoid excess
Funder, J. W. (2017) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2016.03.010 · Cited by 83
Bone mineral density, bone markers, and fractures in adult males with congenital adrenal hyperplasia
Falhammar, H., Filipsson Nyström, H., Wedell, A., Brismar, K., & Thorén, M. (2013) · European Journal of Endocrinology · doi:10.1530/eje-12-0865 · Cited by 82 · cited 2×
“Overall, BMD appears to be reduced at all skeletal sites in CAH, and, as for patients with Addison’s disease, this reduction correlates with cumulative GC exposure in some (289) but not all the studies (290).”
BackgroundLarsson, H., & Ahrén, B. (1999) · Diabetologia · doi:10.1007/s001250051251 · Cited by 73
Hammarstrand, C., Ragnarsson, O., Hallén, T., Andersson, E., Skoglund, T., Nilsson, A. G., Johannsson, G., & Olsson, D. S. (2017) · European Journal of Endocrinology · doi:10.1530/eje-17-0340 · Cited by 70
Pofi, R., Feliciano, C., Sbardella, E., Argese, N., Woods, C. P., Grossman, A. B., Jafar-Mohammadi, B., Gleeson, H., Lenzi, A., Isidori, A. M., et al. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-00529 · Cited by 67
Self-citationGlucocorticoid-induced hypertension: from mouse to man
Whitworth, J. A., Schyvens, C. G., Zhang, Y., Mangos, G. J., & Kelly, J. J. (2001) · Clinical and Experimental Pharmacology and Physiology · doi:10.1046/j.1440-1681.2001.03584.x · Cited by 66
Glucocorticoid use is associated with an increased risk of hypertension
Costello, R. E., Yimer, B. B., Roads, P., Jani, M., & Dixon, W. G. (2021) · Rheumatology · doi:10.1093/rheumatology/keaa209 · Cited by 64 · cited 1×
“In the second study with > 17 000 patients with RA but without hypertension at the time of diagnosis, GC use was associated with an 44% increased risk of hypertension (238).”
BackgroundLawson, A. J., Walker, E. A., Lavery, G. G., Bujalska, I. J., Hughes, B., Arlt, W., Stewart, P. M., & Ride, J. P. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1014934108 · Cited by 61 · cited 1×
“…mutations in the gene encoding 11 β -HSD1 (HSD11B1), or its accessory enzyme hexose-6-phosphate dehydrogenase (H6PDH) that generates its cosubstrate (NADPH) to permit reductase activity (25), develop cortisone reductase deficiency and apparent cortisone reductase deficiency, respectively (494-498).”
BackgroundSystemic glucocorticoid use in Denmark: a population-based prevalence study
Laugesen, K., Jørgensen, J. O. L., Sørensen, H. T., & Petersen, I. (2017) · BMJ Open · doi:10.1136/bmjopen-2016-015237 · Cited by 61
Movahedi, M., Costello, R., Lunt, M., Pye, S. R., Sergeant, J. C., & Dixon, W. G. (2016) · European Journal of Epidemiology · doi:10.1007/s10654-016-0167-1 · Cited by 58
El‐Maouche, D., Collier, S., Prasad, M., Reynolds, J. C., & Merke, D. P. (2015) · Clinical Endocrinology · doi:10.1111/cen.12507 · Cited by 53
Lavery, G. G., Idkowiak, J., Sherlock, M., Bujalska, I., Ride, J. P., Saqib, K., Hartmann, M. F., Hughes, B., Wudy, S. A., De Schepper, J., et al. (2013) · European Journal of Endocrinology · doi:10.1530/eje-12-0628 · Cited by 50
HNF4A modulates glucocorticoid action in the liver
Hunter, A. L., Poolman, T. M., Kim, D., Gonzalez, F. J., Bechtold, D. A., Loudon, A. S. I., Iqbal, M., & Ray, D. W. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110697 · Cited by 49 · cited 2×
“Cell type specificity is conferred by lineage determining factors altering chromatin around such GREs to facilitate productive GR recruitment, a mechanism perhaps best explored in the liver, where the HNF4A factor plays a dominant role (116).”
BackgroundSelf-citationCeccato, F., Barbot, M., Albiger, N., Zilio, M., De Toni, P., Luisetto, G., Zaninotto, M., Greggio, N. A., Boscaro, M., Scaroni, C., et al. (2016) · European Journal of Endocrinology · doi:10.1530/eje-16-0104 · Cited by 42 · cited 1×
“Similarly, in patients with CAH, the cohorts are often heterogeneous, and there is the contribution of androgen excess alongside the impact of GC therapy (287-290).”
BackgroundFardet, L., Kettaneh, A., Gérol, J., Tolédano, C., Tiev, K.-P., & Cabane, J. (2009) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2009.03.009 · Cited by 14
Cited by
The Glucocorticoid Receptor: Isoforms, Functions, and Contribution to Glucocorticoid Sensitivity
Lockett, J., Inder, W. J., & Clifton, V. L. (2024) · Endocrine Reviews · doi:10.1210/endrev/bnae008 · Cited by 135
Sic, A., Cvetkovic, K., Manchanda, E., & Knezevic, N. N. (2024) · Diseases · doi:10.3390/diseases12090220 · Cited by 65
“This approach helps maintain therapeutic levels throughout the day while reducing peak-related side effects [136].”
Background
Metadata
- Authors
- Pofi, R., Caratti, G., Ray, D. W., & Tomlinson, J. W.
- Venue
- Endocrine Reviews
- Publisher
- The Endocrine Society
- Published
- 2023-05-30
- Volume
- 44
- Issue
- 6
- Pages
- 975-1011
- ISSN
- 0163-769X (ISSN-L)
- 1945-7189
- OpenAlex
- W4378782279
- Cited by
- 209
- References
- 124
- FWCI
- 34.58
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.